Journal of Clinical Oncology
Vol. 44, Issue 2
Issue 2
2026
12
Articles
Articles in this Issue
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Matthew J. Maurer, Vit K. Prochazka, Tarec Christoffer El-Galaly et al.
Jan 10, 2026
pp. 117-128
10.1200/jco-25-00892
PURPOSE Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after di...
Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua et al.
Jan 10, 2026
pp. 134-134
10.1200/jco-25-02762
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andres Redondo et al.
Jan 10, 2026
pp. 103-116
10.1200/jco-25-01210
PURPOSE To evaluate atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for recurrent ovarian cancer....
Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity
Priyanka A. Pophali, Vaishalee P. Kenkre, Christi Ann Hayes
Jan 10, 2026
pp. 76-80
10.1200/jco-25-02323
Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?
Kaibo Guo, Jiamin Lu, Xinlei Zhou et al.
Jan 10, 2026
pp. 129-130
10.1200/jco-25-01400
Cost-Utility of Geriatric Assessment and Management in Older Adults With Cancer: Model-Based Economic Evaluation
Selai Akseer, Shant Torkom Yeretzian, Lusine Abrahamyan et al.
Jan 10, 2026
pp. 92-102
10.1200/jco-25-00248
PURPOSE Geriatric assessment and management (GAM) is a guideline-recommended strategy for optimizing cancer management among older adults. A recent cost-utility analysis of the Can...
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
Mark J. Ratain, Antonio Tito Fojo
Jan 10, 2026
pp. 81-85
10.1200/jco-25-01607
FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies
Orhun Akdogan, Osman Sütcüoglu, Tuba Ugur Tuzcu et al.
Jan 10, 2026
pp. 129-129
10.1200/jco-25-01214
Reply to: “FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies,” “Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?,” and “Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN”
Michel Ducreux, Matthieu Texier, Olivier Bouche
Jan 10, 2026
pp. 132-133
10.1200/jco-25-02162
Cost Utility of Geriatric Assessment and Management in Older Adults With Cancer: From Evidence to Implementation
Abu Taher, Alistair Ring, Nicolò Matteo Luca Battisti
Jan 10, 2026
pp. 73-75
10.1200/jco-25-02227
Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN
Federico Nichetti, Letizia Procaccio, Sara Lonardi et al.
Jan 10, 2026
pp. 130-131
10.1200/jco-25-01517
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Richard T. Maziarz, Michael R. Bishop, Constantine S. Tam et al.
Jan 10, 2026
pp. 86-91
10.1200/jco-25-00507
We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JUL...
All Issues
Issue 9
- Issue 9
14
Issue 8
- Issue 8
16
Issue 7_suppl
- Issue 7_suppl
886
Issue 7
- Issue 7
17
Issue 6
- Issue 6
15
Issue 5
- Issue 5
15
Issue 4
- Issue 4
13
Issue 3
- Issue 3
13
Issue 24
- Issue 24
18
Issue 23
- Issue 23
16
Issue 22
- Issue 22
15
Issue 21
- Issue 21
14
Issue 20
- Issue 20
18
Issue 2_suppl
- Issue 2_suppl
818
Issue 2
- Issue 2
12
Issue 19_suppl
- Issue 19_suppl
340
Issue 19
- Issue 19
16
Issue 18
- Issue 18
16
Issue 17_suppl
- Issue 17_suppl
60
Issue 17
- Issue 17
17
Issue 16_suppl
- Issue 16_suppl
7213
Issue 16
- Issue 16
15
Issue 15
- Issue 15
13
Issue 14
- Issue 14
14
Issue 13
- Issue 13
14
Issue 12
- Issue 12
16
Issue 11
- Issue 11
15
Issue 10
- Issue 10
14
Issue 1
- Issue 1
11
Issue 9
- Issue 9
15
Issue 8
- Issue 8
19
Issue 7
- Issue 7
19
Issue 6
- Issue 6
20
Issue 5_suppl
- Issue 5_suppl
869
Issue 5
- Issue 5
21
Issue 4_suppl
- Issue 4_suppl
824
Issue 4
- Issue 4
18
Issue 36
- Issue 36
12
Issue 35
- Issue 35
12
Issue 34
- Issue 34
12
Issue 33
- Issue 33
14
Issue 32
- Issue 32
17
Issue 31
- Issue 31
16
Issue 30
- Issue 30
14
Issue 3
- Issue 3
17
Issue 29
- Issue 29
16
Issue 28
- Issue 28
16
Issue 27
- Issue 27
14
Issue 26
- Issue 26
13
Issue 25
- Issue 25
17
Issue 24
- Issue 24
19
Issue 23
- Issue 23
14
Issue 22
- Issue 22
14
Issue 21
- Issue 21
13
Issue 20
- Issue 20
12
Issue 2
- Issue 2
18
Issue 19
- Issue 19
12
Issue 18
- Issue 18
14
Issue 17_suppl
- Issue 17_suppl
57
Issue 17
- Issue 17
15
Issue 16_suppl
- Issue 16_suppl
6439
Issue 16
- Issue 16
14
Issue 15
- Issue 15
16
Issue 14
- Issue 14
17
Issue 13
- Issue 13
17
Issue 12
- Issue 12
15
Issue 11
- Issue 11
18
Issue 10
- Issue 10
14
Issue 1
- Issue 1
20
Journal Info
Publisher
Lippincott Williams & Wilkins
ISSN
0732-183X
E-ISSN
1527-7755
Subject
Health Sciences
Language
English